Patent Application
20220362316
The present invention relates to a pharmaceutical composition for treating cancer, comprising, as active ingredients, an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea.
Oncolytic viruses have excellent tumor-specific targeting ability, proliferation ability in cancer cells, and cancer cell-killing ability. Recently, various clinical studies based on oncolytic viruses have been conducted. In the year 2015, an era of oncolytic virus field began in the US and Europe, as talimogene laherparepvec (T-Vec), which is an oncolytic virus based on herpes simplex virus, was successfully commercialized as a therapeutic agent for advanced melanoma.
Recently, the usefulness of oncolytic viruses exceeds their own efficacy and the viruses activate tumor immunity, thereby showing their potential as a therapeutic agent that is used in combination with another immunotherapeutic agent. Until the year 2000 that was an early stage of development of oncolytic viruses, a direct killing effect of the viruses, which is caused by cancer cell-specific proliferation thereof, was relatively more important. However, subsequent clinical studies have found that the key mechanism of oncolytic viruses was the activation of tumor immunity rather than the direct cancer cell-killing effect. Based on this finding, therapies, in which an oncolytic virus is administered in combination with an immunotherapeutic agent such as an immune checkpoint inhibitor, have recently been developed. It is known that such therapies are possible because the oncolytic virus converts the tumor microenvironment, in which immunity is suppressed, into a tumor microenvironment suitable for immunotherapy.
In a number of clinical studies on vaccinia virus-based oncolytic viruses, oncolytic virus therapy may result in acute tumor necrosis, durable response, or complete response, but in some cases, may lead to a difficult-to-predict result (pharmacodynamics variability) such as progressive disease or early death. For example, for Pexa-vec that is based on a vaccinia virus, in the phase 1 clinical trial, some patients died prematurely within a month after the oncolytic virus therapy and this was associated with persistent systemic inflammatory response and main organs dysfunction. Therefore, in order to enhance the therapeutic effect of an oncolytic virus, it is necessary to understand interactions between cancer cells, the patient's immune status, and the oncolytic virus; and based on this understanding, there is a need for research on techniques capable of increasing clinical efficacy of the oncolytic virus.
Accordingly, as a resulting of conducting studies to enhance the anticancer effects of oncolytic viruses, the present inventors have found that excellent anticancer effect and safety are obtained in a case where an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea are co-administered to an individual with cancer, as compared with a conventional case where an oncolytic virus is administered alone, or an oncolytic virus and an immune checkpoint inhibitor are co-administered, thereby completing the present invention.
To achieve the above-mentioned object, in an aspect of the present invention, there is provided a pharmaceutical composition for treating cancer, comprising, as active ingredients, an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea.
In another aspect of the present invention, there is provided a kit for treating cancer, comprising a first composition that includes an oncolytic virus as an active ingredient, a second composition that includes hydroxyurea as an active ingredient, and a third composition that includes an immune checkpoint inhibitor as an active ingredient.
In yet another aspect of the present invention, there is provided a method for treating cancer, comprising administering, to an individual with cancer, an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea.
In still yet another aspect of the present invention, there is provided a use of a composition, which includes an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea, for the prevention or treatment of cancer.
In still yet another aspect of the present invention, there is provided a use of a composition, which includes an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea, for the manufacture of a medicament for preventing or treating cancer.
The pharmaceutical composition for treating cancer, which comprises, as active ingredients, an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea, of the present invention has excellent anticancer effect and safety as compared with a conventional case where an oncolytic virus is administered alone or an oncolytic virus and an immune checkpoint inhibitor are co-administered. Accordingly, the pharmaceutical composition, which comprises, as active ingredients, an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea, of the present invention may be effectively used for the treatment of cancer.
Hereinafter, the present invention will be described in detail.
In an aspect of the present invention, there is provided a pharmaceutical composition for treating cancer, comprising, as active ingredients, an oncolytic virus, an immune checkpoint inhibitor (ICI), and hydroxyurea.
The oncolytic virus, the immune checkpoint inhibitor, and the hydroxyurea, which are included in the pharmaceutical composition, may be co-administered simultaneously, sequentially, or in reverse order.
Specifically, the oncolytic virus, the immune checkpoint inhibitor, and the hydroxyurea may be administered simultaneously. In addition, the hydroxyurea may be administered first, followed by the immune checkpoint inhibitor, and then the oncolytic virus. The hydroxyurea may be administered first, followed by the oncolytic virus, and then the immune checkpoint inhibitor. The hydroxyurea may be administered first, followed by simultaneous administration of the oncolytic virus and the immune checkpoint inhibitor.
Furthermore, the oncolytic virus may be administered first, followed by the hydroxyurea, and then the immune checkpoint inhibitor. The oncolytic virus may be administered first, followed by the immune checkpoint inhibitor, and then the hydroxyurea. The oncolytic virus may be administered first, followed by simultaneous administration of the hydroxyurea and the immune checkpoint inhibitor.
In addition, the immune checkpoint inhibitor may be administered first, followed by the hydroxyurea, and then the oncolytic virus. The immune checkpoint inhibitor may be administered first, followed by the oncolytic virus, and then the hydroxyurea. The immune checkpoint inhibitor may be administered first, followed by simultaneous administration of the oncolytic virus and the hydroxyurea.
Furthermore, the hydroxyurea may be administered first, followed by the oncolytic virus, followed by the immune checkpoint inhibitor, and then the hydroxyurea again. The hydroxyurea may be administered first, followed by the immune checkpoint inhibitor, followed by the oncolytic virus, and then the hydroxyurea again. The hydroxyurea may be administered first, followed by simultaneous administration of the oncolytic virus and the immune checkpoint inhibitor, and then the hydroxyurea again.
In addition, the hydroxyurea may be administered first, followed by the oncolytic virus, followed by the hydroxyurea again, and then the immune checkpoint inhibitor. The hydroxyurea may be administered first, followed by the immune checkpoint inhibitor, followed by the hydroxyurea again, and then the oncolytic virus.
Furthermore, the hydroxyurea may be administered first, followed by the oncolytic virus, followed by the hydroxyurea again, followed by the immune checkpoint inhibitor, and then the hydroxyurea again. The hydroxyurea may be administered first, followed by the immune checkpoint inhibitor, followed by the hydroxyurea again, followed by the oncolytic virus, and then the hydroxyurea again.
In addition, the oncolytic virus may be administered first, followed by the hydroxyurea, followed by the immune checkpoint inhibitor, and then the hydroxyurea again. The immune checkpoint inhibitor may be administered first, followed by the hydroxyurea, followed by the oncolytic virus, and then the hydroxyurea again.
The oncolytic virus may be derived from adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus. Preferably, the oncolytic virus may be derived from vaccinia virus, herpes simplex virus, or adenovirus.
The vaccinia virus may be, but is not limited to, one of the following vaccinia virus strains: Western Reserve (WR), New York vaccinia virus (NYVAC), Wyeth (The New York City Board of Health; NYCBOH), LC16m8, Lister, Copenhagen, Tian Tan, USSR, TashKent, Evans, International Health Division-J (IHD-J), and International Health Division-White (IHD-W). In an embodiment of the present invention, the Western Reserve strain vaccinia virus and the Wyeth strain vaccinia virus were used.
The oncolytic virus may be a wild-type virus or a recombinant virus. Specifically, the recombinant virus may be obtained by deleting at least one gene of the wild-type virus or inserting at least one foreign gene thereinto. Here, the at least one gene of the wild-type virus may be a gene related to viral virulence which encodes any one selected from the group consisting of thymidine kinase (TK), vaccinia growth factor (VGF), WR53.5, F13.5L, F14.5, A56R, B18R, and combinations thereof.
In addition, the at least one foreign gene may be an immune-promoting gene that encodes any one selected from the group consisting of herpes simplex virus thymidine kinase (HSV-TK), HSV-TK variant, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), cytosine deaminase (CD), carboxylesterase 1, carboxylesterase 2, interferon beta (INF-β), somatostatin receptor 2, and combinations thereof.
Specifically, the recombinant virus may be obtained by deleting TK gene in adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus. In an embodiment of the present invention, a recombinant virus obtained by deleting TK gene in a Western Reserve strain vaccinia virus was used, and this recombinant virus was designated as “WR VVtk−”. In addition, in an embodiment of the present invention, a recombinant virus obtained by deleting TK gene in a Wyeth strain vaccinia virus was used, and this recombinant virus was designated as “Wyeth VVtk−”.
In addition, the recombinant virus may be obtained by deleting TK gene and VGF gene in adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus.
Furthermore, the recombinant virus may be obtained by deleting TK gene in and inserting HSV-TK gene into adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus.
In addition, the recombinant virus may be obtained by deleting TK gene in and inserting an HSV-TK variant gene into adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus. In an embodiment of the present invention, a recombinant virus was used, which is obtained by deleting TK gene in a Western Reserve strain vaccinia virus and inserting, into the deleted position, a gene that is represented by SEQ ID NO: 1 and encodes an HSV-TK variant, and this recombinant virus was designated as “WOTS-418”.
Furthermore, the recombinant virus may be obtained by deleting TK gene in and inserting GM-CSF gene into adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus.
In addition, the recombinant virus may be obtained by deleting TK gene in and inserting G-CSF gene into adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus.
Furthermore, the recombinant virus may be obtained by deleting TK gene in and inserting cytosine deaminase (CD) gene into adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus.
In addition, the recombinant virus may be obtained by deleting TK gene in and inserting somatostatin receptor 2 gene into adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus.
Furthermore, the recombinant virus may be obtained by deleting TK gene in and inserting any two or more genes selected from the group consisting of genes, each of which encodes herpes simplex virus thymidine kinase (HSV-TK), an HSV-TK variant, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), cytosine deaminase (CD), or somatostatin receptor 2, into adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus.
In addition, the recombinant virus may be obtained by deleting TK gene and VGF gene in and inserting any one gene selected from the group consisting of genes, each of which encodes HSV-TK, an HSV-TK variant, GM-CSF, G-CSF, CD, or somatostatin receptor 2, and combinations thereof, into adenovirus, herpes simplex virus, measles virus, lentivirus, retrovirus, cytomegalovirus, baculovirus, adeno-associated virus, myxoma virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, parvovirus, coxsackievirus, senecavirus, vaccinia virus, or orthopoxvirus.
As used herein, the term “gene deletion” means that a gene is not expressed due to partial or complete deletion of the gene, or insertion of a foreign gene thereinto. In a case where partial deletion occurs in the gene, some amino acids at the N-terminus or C-terminus of a polypeptide expressed by the gene may be deleted.
As used herein, the term “thymidine kinase (TK)” refers to an enzyme that is called thymidine kinase and involved in nucleotide biosynthesis. The TK is an enzyme used for nucleotide biosynthesis in both cells and viruses. Here, for the cells, normal cells do not divide anymore, and thus no TK exists therein; and even for rapidly dividing cells such as hair follicle cells, TK is not present in an amount sufficient for viruses to utilize. From these viewpoints, a virus is allowed to proliferate only in the presence of cancer cells, in which TK is present, by deletion of TK gene therein, so that the cancer cells may be selectively killed.
As used herein, the term “vaccinia growth factor (VGF)” refers to a polypeptide that has sequence homology to epidermal growth factor and stimulates cell proliferation around infected cells. A vaccinia virus replicates better in proliferating cells, and thus may be advantageously used for viral replication in vivo. In order to cause an oncolytic virus to proliferate more specifically only in cancer cells, the virus may additionally undergo deletion of VGF gene in addition to deletion of the TK gene.
As used herein, the term “GM-CSF”, which is called granulocyte-macrophage colony-stimulating factor, refers to a protein secreted by macrophages, T cells, mast cells, natural killer cells, endothelial cells, and fibroblasts. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, basophils, eosinophils) and monocytes. In addition, GM-CSF rapidly increases the number of macrophages, thereby inducing an immune response. The GM-CSF may be of human origin and may be a protein having the sequence of GenBank: AAA52578.1.
As used herein, the term “CD”, which is called cytosine deaminase, refers to an enzyme that catalyzes hydrolytic deamination of cytosine into uracil and ammonia.
As used herein, the term “G-CSF”, which is called granulocyte colony-stimulating factor, refers to a cytokine produced by macrophages, fibroblasts, endothelial cells, and the like upon stimulation by inflammation or endotoxin. The G-CSF promotes production of neutrophils. The G-CSF may be of human origin (rhGCSF) and may be a protein having the sequence of GenBank: AAA03056.1.
As used herein, the term “somatostatin receptor 2” refers to a protein encoded by SSTR2 gene in humans. The somatostatin receptor 2 is expressed mainly in tumors, and patients with neuroendocrine tumors, who overexpress somatostatin receptor 2, show improved prognosis. The somatostatin receptor 2 has capacity to stimulate apoptosis in many cells, including cancer cells.
As used herein, the term “hydroxyurea” refers to a compound having the following formula.
The hydroxyurea is known as an anticancer agent that inhibits DNA synthesis; however, the exact mechanism thereof is not elucidated. In addition, the hydroxyurea may be included in the pharmaceutical composition in the form of a commercialized drug that contains hydroxyurea. Examples of the commercialized drug that contains hydroxyurea may include, but are not limited to, Hydroxyurea®, Hydrea®, Droxia™, Mylocel™, Siklos®, and Hydrine® capsule. The hydroxyurea may be taken orally, and parenteral administration thereof is also possible.
A dosage of the oncolytic virus varies depending on the individual's condition and body weight, the severity of disease, the type of drug, the route and period of administration, and may be appropriately selected by a person skilled in the art. The dosage may be such that a patient receives a vaccinia virus at 1×105 to 1×1018 of virus particles, infectious virus units (TCID50), or plaque forming units (pfu). Specifically, the dosage may be such that a patient receives an oncolytic virus at 1×105, 2×105, 5×105, 1×106, 2×106, 5×106, 1×107, 2×107, 5×107, 1×108, 2×108, 5×108, 1×109, 2×109, 5×109, 1×1010, 5×1010, 1×1011, 5×1011, 1×1012, 1×1013, 1×1014, 1×1015, 1×1016, 1×1017, or higher of virus particles, infectious virus units, or plaque forming units, and various numerical values and ranges between the above-mentioned numerical values may also be included therein. Preferably, the oncolytic virus may be administered at a dose of 1×105 to 1×1010 pfu. More preferably, the oncolytic virus may be administered at a dose of equal to or greater than 1×105 and lower than 1×109 pfu. In an embodiment of the present invention, the oncolytic virus was administered at 1×105 or ×107 pfu.
In addition, the hydroxyurea may be administered at a dose of 1 mg/kg/day to 100 mg/kg/day, or 10 mg/kg/day to 90 mg/kg/day. Specifically, the hydroxyurea may be administered at a dose of 10 mg/kg/day to 90 mg/kg/day, 15 mg/kg/day to 80 mg/kg/day, 20 mg/kg/day to 70 mg/kg/day, 25 mg/kg/day to 65 mg/kg/day, or 30 mg/kg/day to 60 mg/kg/day. In an embodiment of the present invention, the hydroxyurea was administered at 30 mg/kg/day or 60 mg/kg/day. Depending on the dosage, the hydroxyurea may be administered in divided doses several times a day. Specifically, the hydroxyurea may be administered 1 to 4 times a day or 1 to 2 times a day.
The immune checkpoint inhibitor refers to a substance that inhibits the mechanism of cancer cells which interferes with activation of T cells, and may be any one selected from the group consisting of anti-PD-L1 antibody, anti-PD-1 antibody, anti-CTLA4 antibody, anti-PD-L2 antibody, LTF2 control antibody, anti-LAG3 antibody, anti-A2aR antibody, anti-TIGIT antibody, anti-TIM-3 antibody, anti-B7-H3 antibody, anti-B7-H4 antibody, anti-VISTA antibody, anti-CD47 antibody, anti-BTLA antibody, anti-KIR antibody, anti-IDO antibody, and combinations thereof.
Cancer cells hijack the immune checkpoint system as a mechanism to evade immune responses. Specifically, cancer cells use immune checkpoint receptors to evade immune responses, and representative examples of the immune checkpoint receptor include PD-L1, PD-1, CTLA-4, and the like. In order to prevent these cancer cells from evading immunity, an immune checkpoint inhibitor, which is a molecule that specifically binds to an immune checkpoint receptor, is used for the treatment of cancer. The first immune checkpoint inhibitor was ipilimumab (Yervoy®), which is a monoclonal antibody that specifically binds to cytotoxic T-lymphocyte associated antigen-4 (CTLA-4). The next developed immune checkpoint therapeutic agents were monoclonal antibodies against programmed cell death-1 (PD-1) and a ligand thereof, that is, programmed death ligand-1 (PD-L1). As representative drugs, anti-PD-1 antibodies such as nivolumab (Opdivo®) and pembrolizumab (Keytruda®), and anti-PD-L1 antibodies such as avelumab (Bavencio®), atezolizumab (Tecentriq®), and durvalumab (Imfinzi®) may be mentioned.
In addition, research has been conducted on monoclonal antibodies that specifically bind to various immune checkpoint receptors such as glucocorticoid-induced TNFR-related protein (GITR), killer cell immunoglobulin-like receptor (KIR), lymphocyte-activation gene-3 (LAG-3), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and tumor-necrosis factor receptor superfamily member 4 (TNFRSF4).
Administration of the immune checkpoint inhibitor may be performed in compliance with the usage and dose set by each manufacturer. The immune checkpoint inhibitor may be administered at a dose of 0.1 mg/kg to 10 mg/kg, or 1 mg/kg to 5 mg/kg. For example, for Opdivo Injection. that contains nivolumab as an active ingredient, 3 mg/kg may be administered via intravenous instillation over 60 minutes at 2-week intervals; and the usage and dose thereof as a combination therapy may be such that 1 mg/kg is administered via intravenous instillation over 30 minutes. In addition, for Keytruda Injection. that contains pembrolizumab as an active ingredient, 200 mg may be administered via intravenous instillation over 30 minutes at 3-week intervals. As such, even with the same anti-PD-1 antibody, the usage and dose thereof vary depending on the product. Thus, administration thereof is preferably performed in compliance with the usage and dose set by each manufacturer.
The cancer may be solid cancer or blood cancer. Specifically, the blood cancer may be any one selected from the group consisting of lymphoma, acute leukemia, and multiple myeloma. The solid cancer may be any one selected from the group consisting of lung cancer, colorectal cancer, prostate cancer, thyroid cancer, breast cancer, brain cancer, head and neck cancer, esophageal cancer, skin cancer, thymic cancer, gastric cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, rectal cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer, and combinations thereof.
In addition, the pharmaceutical composition of the present invention may further comprise a physiologically acceptable carrier. In addition, the pharmaceutical composition of the present invention may further comprise suitable excipients and diluents commonly used in the preparation of pharmaceutical compositions. In addition, the pharmaceutical composition may be formulated in the form of an injection according to a conventional method.
In a case of being formulated as preparations for parenteral administration, the pharmaceutical composition may be formulated into sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, or the like. For the non-aqueous solution or the suspension, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, or the like may be used. As the base of the suppository, Witepsol™, macrogol, Tween™ 61, cacao butter, laurin fat, glycerogelatin, or the like may be used.
Regarding the administration route, dosage, and frequency of administration, the pharmaceutical composition may be administered to a subject in a variety of ways and amounts depending on the patient's condition and the presence or absence of side effects; and the optimal administration route, dosage, and frequency of administration therefor may be selected by a person skilled in the art within a suitable range. In addition, the pharmaceutical composition may be administered in combination with another drug or physiologically active substance whose therapeutic effect is known for the disease to be treated, or may be formulated in the form of a combination preparation with the other drug.
The pharmaceutical composition may be administered parenterally, and such administration may be performed by any suitable method, such as intratumoral, intraperitoneal, subcutaneous, intradermal, intranodal, intravenous, or intraarterial administration. Among these, intratumoral, intraperitoneal, or intravenous administration may be preferred. On the other hand, the dosage of the pharmaceutical composition may be determined depending on the administration schedule, the total dosage, and the patient's health condition.
In another aspect of the present invention, there is provided a kit for treating cancer, comprising a first composition that includes an oncolytic virus as an active ingredient, a second composition that includes hydroxyurea as an active ingredient, and a third composition that includes an immune checkpoint inhibitor as an active ingredient.
The oncolytic virus, the immune checkpoint inhibitor, and the hydroxyurea are as described above for the pharmaceutical composition.
A dosage of the first composition varies depending on the individual's condition and body weight, the severity of disease, the type of drug, the route and period of administration, and may be appropriately selected by a person skilled in the art. The dosage may be such that a patient receives a vaccinia virus at 1×105 to 1×1018 of virus particles, infectious virus units (TCID50), or plaque forming units (pfu). Specifically, the dosage may be such that a patient receives an oncolytic virus at 1×105, 2×105, 5×105, 1×106, 2×106, 5×106, 1×107, 2×107, 5×107, 1×108, 2×108, 5×108, 1×109, 2×109, 5×109, 1×1010, 5×1010, 1×1011, 5×1011, 1×1012, 1×1013, 1×1014, 1×1015, 1×1016, 1×1017, or higher of virus particles, infectious virus units, or plaque forming units, and various numerical values and ranges between the above-mentioned numerical values may also be included therein. Preferably, the oncolytic virus may be administered at a dose of 1×105 to 1×1010 pfu. More preferably, the oncolytic virus may be administered at a dose of equal to or greater than 1×105 and lower than 1×109 pfu. In an embodiment of the present invention, the first composition was administered at 1×105 or ×107 pfu.
In addition, the second composition may be administered at a dose of 1 mg/kg/day to 100 mg/kg/day, or 10 mg/kg/day to 90 mg/kg/day. Specifically, the second composition may be administered at a dose of 10 mg/kg/day to 90 mg/kg/day, 15 mg/kg/day to 80 mg/kg/day, 20 mg/kg/day to 70 mg/kg /day, 25 mg/kg/day to 65 mg/kg/day, or 30 mg/kg/day to 60 mg/kg/day. In an embodiment of the present invention, the second composition was administered at 30 mg/kg/day or 60 mg/kg/day. Depending on the dosage, the second composition may be administered in divided doses several times a day. Specifically, the second composition may be administered 1 to 4 times a day or 1 to 2 times a day.
Administration of the third composition may be performed in compliance with the usage and dose of an immune checkpoint inhibitor included in the third composition, which are set by each manufacturer. The dosage of the third composition may be 0.1 mg/kg to 10 mg/kg, or 1 mg/kg to 5 mg/kg.
The cancer may be solid cancer or blood cancer. Specifically, the blood cancer may be any one selected from the group consisting of lymphoma, acute leukemia, and multiple myeloma. The solid cancer may be any one selected from the group consisting of lung cancer, colorectal cancer, prostate cancer, thyroid cancer, breast cancer, brain cancer, head and neck cancer, esophageal cancer, skin cancer, thymic cancer, gastric cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, rectal cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer, and combinations thereof.
The first composition, the second composition, and the third composition may further comprise a physiologically acceptable carrier. In addition, the pharmaceutical composition of the present invention may further comprise suitable excipients and diluents commonly used in the preparation of pharmaceutical compositions. In addition, the pharmaceutical composition may be formulated in the form of an injection according to a conventional method.
In a case of being formulated as preparations for parenteral administration, the first composition, the second composition, and the third composition may be formulated into sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, or the like. For the non-aqueous solution or the suspension, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, or the like may be used. As the base of the suppository, Witepsol™, macrogol, Tween™ 61, cacao butter, laurin fat, glycerogelatin, or the like may be used.
Regarding the administration route, total dosage, and frequency of administration, the first composition, the second composition, and the third composition may be administered to a subject in a variety of ways and amounts depending on the patient's condition and the presence or absence of side effects; and the optimal administration route, dosage, and frequency of administration therefor may be selected by a person skilled in the art within a suitable range. In addition, the pharmaceutical composition may be administered in combination with another drug or physiologically active substance whose therapeutic effect is known for the disease to be treated, or may be formulated in the form of a combination preparation with the other drug.
The first composition, the second composition, and the third composition may be administered parenterally, and such administration may be performed by any suitable method, such as intratumoral, intraperitoneal, subcutaneous, intradermal, intranodal, intravenous, or intraarterial administration. Among these, intratumoral, intraperitoneal, or intravenous administration may be preferred. On the other hand, dosages of the first composition, the second composition, and the third composition may be determined depending on the administration schedule, the total dosage, and the patient's health condition.
In addition, the first composition may be administered twice to an individual, and the administration may be performed at intervals of 7 to 30 days. Specifically, the first composition may be administered at intervals of 7 days, 14 days, 21 days, or 30 days.
The second composition may be administered before or after administration of the first composition. Specifically, the second composition may be continuously administered once a day starting from 3 to 5 days before administration of the first composition, and may be continuously administered once a day for 9 to 28 days starting from within 24 hours of or after 24 hours of administration of the first composition. In an embodiment of the present invention, the second composition may be continuously administered once a day starting from 1 to 3 days before administration of the first composition, and may be administered once a day for 13 days, 17 days, 18 days, or 28 days after administration of the first composition.
The third composition may be continuously administered at least once a week for 1 to 10 weeks after administration of the first composition. Specifically, the third composition may be administered continuously at least twice a week for 1 to 8 weeks after administration of the first composition.
In yet another aspect of the present invention, there is provided a method for treating cancer, comprising administering, to an individual with cancer, an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea.
The oncolytic virus, the immune checkpoint inhibitor, and the hydroxyurea are as described above for the pharmaceutical composition.
The oncolytic virus, the immune checkpoint inhibitor, and the hydroxyurea may be co-administered simultaneously, sequentially, or in reverse order. Specifically, the oncolytic virus, the immune checkpoint inhibitor, and the hydroxyurea may be administered simultaneously. In addition, the hydroxyurea may be administered first, followed by the immune checkpoint inhibitor, and then the oncolytic virus. The hydroxyurea may be administered first, followed by the oncolytic virus, and then the immune checkpoint inhibitor. The hydroxyurea may be administered first, followed by simultaneous administration of the oncolytic virus and the immune checkpoint inhibitor.
Furthermore, the oncolytic virus may be administered first, followed by the hydroxyurea, and then the immune checkpoint inhibitor. The oncolytic virus may be administered first, followed by the immune checkpoint inhibitor, and then the hydroxyurea. The oncolytic virus may be administered first, followed by simultaneous administration of the hydroxyurea and the immune checkpoint inhibitor.
In addition, the immune checkpoint inhibitor may be administered first, followed by the hydroxyurea, and then the oncolytic virus. The immune checkpoint inhibitor may be administered first, followed by the oncolytic virus, and then the hydroxyurea. The immune checkpoint inhibitor may be administered first, followed by simultaneous administration of the oncolytic virus and the hydroxyurea.
Furthermore, the hydroxyurea may be administered first, followed by the oncolytic virus, followed by the immune checkpoint inhibitor, and then the hydroxyurea again. The hydroxyurea may be administered first, followed by the immune checkpoint inhibitor, followed by the oncolytic virus, and then the hydroxyurea again. The hydroxyurea may be administered first, followed by simultaneous administration of the oncolytic virus and the immune checkpoint inhibitor, and then the hydroxyurea again.
In addition, the hydroxyurea may be administered first, followed by the oncolytic virus, followed by the hydroxyurea again, and then the immune checkpoint inhibitor. The hydroxyurea may be administered first, followed by the immune checkpoint inhibitor, followed by the hydroxyurea again, and then the oncolytic
Furthermore, the hydroxyurea may be administered first, followed by the oncolytic virus, followed by the hydroxyurea again, followed by the immune checkpoint inhibitor, and then the hydroxyurea again. The hydroxyurea may be administered first, followed by the immune checkpoint inhibitor, followed by the hydroxyurea again, followed by the oncolytic virus, and then the hydroxyurea again.
In addition, the oncolytic virus may be administered first, followed by the hydroxyurea, followed by the immune checkpoint inhibitor, and then the hydroxyurea again. The immune checkpoint inhibitor may be administered first, followed by the hydroxyurea, followed by the oncolytic virus, and then the hydroxyurea again.
A dosage of the oncolytic virus varies depending on the individual's condition and body weight, the severity of disease, the type of drug, the route and period of administration, and may be appropriately selected by a person skilled in the art. The dosage may be such that a patient receives a vaccinia virus at 1×105 to 1×1018 of virus particles, infectious virus units (TCID50), or plaque forming units (pfu). Specifically, the dosage may be such that a patient receives an oncolytic virus at 1×105, 2×105, 5×105, 1×106, 7×106, 5×106, 1×107, 2×107, 5×107, 1×108, 2×108, 5×108, 1×109, 2×109, 5×109, 1×1010, 5×1010, 1×1011, 5×1011, 1×1012, 1×1013, 1×1014, 1×1015, 1×1016, 1×1017, or higher of virus particles, infectious virus units, or plaque forming units, and various numerical values and ranges between the above-mentioned numerical values may also be included therein. Preferably, the oncolytic virus may be administered at a dose of 1×105 to 1×1010 pfu. More preferably, the oncolytic virus may be administered at a dose of equal to or greater than 1×105 and lower than 1×109 pfu. In an embodiment of the present invention, the oncolytic virus was administered at 1×105 or ×107 pfu.
In addition, the hydroxyurea may be administered at a dose of 1 mg/kg/day to 100 mg/kg/day, or 10 mg/kg/day to 90 mg/kg/day. Specifically, the hydroxyurea may be administered at a dose of 10 mg/kg/day to 90 mg/kg/day, 15 mg/kg/day to 80 mg/kg/day, 20 mg/kg/day to 70 mg/kg /day, 25 mg/kg/day to 65 mg/kg/day, or 30 mg/kg/day to 60 mg/kg/day. In an embodiment of the present invention, the hydroxyurea was administered at 30 mg/kg/day or 60 mg/kg/day. Depending on the dosage, the hydroxyurea may be administered in divided doses several times a day. Specifically, the hydroxyurea may be administered 1 to 4 times a day or 1 to 2 times a day.
Administration of the immune checkpoint inhibitor may be performed in compliance with the usage and dose set by each manufacturer. The immune checkpoint inhibitor may be administered at a dose of 0.1 mg/kg to 10 mg/kg, or 1 mg/kg to 5 mg/kg. For example, for Opdivo Injection. that contains nivolumab as an active ingredient, 3 mg/kg may be administered via intravenous instillation over 60 minutes at 2-week intervals; and the usage and dose thereof as a combination therapy may be such that 1 mg/kg is administered via intravenous instillation over 30 minutes. In addition, for Keytruda Injection. that contains pembrolizumab as an active ingredient, 200 mg may be administered via intravenous instillation over 30 minutes at 3-week intervals. As such, even with the same anti-PD-1 antibody, the usage and dose thereof vary depending on the product. Thus, administration thereof is preferably performed in compliance with the usage and dose set by each manufacturer.
In addition, the oncolytic virus may be administered 1 to 10 times or 2 to 5 times, and may be administered to an individual at intervals of 7 to 30 days. Specifically, the oncolytic virus may be administered at intervals of 7 days, 14 days, 21 days, or 30 days.
The hydroxyurea may be administered before, during, or after administration of the oncolytic virus. Specifically, the hydroxyurea may be administered before or after administration of the oncolytic virus. The hydroxyurea may be continuously administered once a day starting from 3 to 5 days before administration of the oncolytic virus, and may be continuously administered once a day for 9 to 28 days starting from within 24 hours of or after 24 hours of administration of the oncolytic virus. In an embodiment of the present invention, the hydroxyurea may be continuously administered once a day starting from 1 to 3 days before administration of the oncolytic virus, and may be administered once a day for 13 days, 17 days, 18 days, or 28 days after administration of the oncolytic virus.
The immune checkpoint inhibitor may be administered before, during, or after administration of the oncolytic virus. Specifically, the immune checkpoint inhibitor may be administered after administration of the oncolytic virus. The immune checkpoint inhibitor may be continuously administered at least once a week for 1 to 10 weeks after administration of the oncolytic virus. Specifically, the immune checkpoint inhibitor may be administered continuously at least twice a week for 1 to 8 weeks after administration of the oncolytic virus.
The cancer may be solid cancer or blood cancer. Specifically, the blood cancer may be any one selected from the group consisting of lymphoma, acute leukemia, and multiple myeloma. The solid cancer may be any one selected from the group consisting of lung cancer, colorectal cancer, prostate cancer, thyroid cancer, breast cancer, brain cancer, head and neck cancer, esophageal cancer, skin cancer, thymic cancer, gastric cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, rectal cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer, and combinations thereof.
The hydroxyurea may be administered orally or parenterally. Specifically, the hydroxyurea may be administered parenterally, and such administration may be performed intraperitoneally or intravenously.
In addition, the immune checkpoint inhibitor may be administered intraperitoneally or intravenously.
The oncolytic virus may be administered parenterally, and such administration may be performed by any suitable method, such as intratumoral, intraperitoneal, subcutaneous, intradermal, intranodal, intravenous, or intraarterial administration. Among these, intratumoral, intraperitoneal, or intravenous administration may be preferred. Meanwhile, the dosages of the oncolytic virus, the immune checkpoint inhibitor, and the hydroxyurea may be determined according to the administration schedule, the dosage, and the patient's health condition.
As used herein, the term “individual” refers to a person who has or is suffering from a disease in a state that may be alleviated, inhibited, or treated by administering the pharmaceutical composition of the present invention.
As used herein, the term “administration” means introducing an effective amount of a substance into an individual by an appropriate method, and administration of the vaccinia virus and the hydroxyurea may be performed via a common route that allows the substances to reach a target tissue.
In addition, the oncolytic virus, the immune checkpoint inhibitor, and the hydroxyurea may be administered in combination with another drug or physiologically active substance whose therapeutic effect is known for the disease to be treated, or may be formulated in the form of a combination preparation with the other drug.
In still yet another aspect of the present invention, there is provided a use of a composition, which includes an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea, for the prevention or treatment of cancer.
In still yet another aspect of the present invention, there is provided a use of a composition, which includes an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea, for the manufacture of a medicament for treating cancer.
Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are for illustrative purposes only, and the scope of the present invention is not limited thereto.
To produce oncolytic viruses in which thymidine kinase (TK) gene is deleted, the wild-type vaccinia viruses, that is, Wyeth strain (NYC Department of Health) and Western Reserve strain were purchased from the American Type Culture Collection (ATCC). For recombination, a TK region in the wild-type vaccinia virus was subjected to substitution using a shuttle plasmid vector that contains firefly luciferase reporter (p7.5 promoter) gene or GFP gene.
To obtain oncolytic viruses, HeLa cells (ATCC) were seeded in 6-well plates at 4×105 cells per well, and then culture was performed in EMEM medium containing 10% fetal bovine serum. Subsequently, treatment with the wild-type vaccinia virus was performed at an MOI of 0.05. 2 hours later, the medium was replaced with EMEM medium containing 2% fetal bovine serum, and then the cells were transfected with 4 μg of the shuttle plasmid vector, which was constructed in Preparation Example 1.1 and linearized, using Xfect™ polymer (Clonetech 631317, USA). Culture was performed for 4 hours. Subsequently, the medium was replaced with EMEM medium containing 2% fetal bovine serum, and then culture was performed for 72 hours. Finally, the infected cells were collected, and then freezing and thawing were repeated 3 times. Subsequently, the cells were lysed by sonication, and a sucrose cushion method was used to obtain free oncolytic viruses, which were designated Wyeth VVtk− or WR VVtk−.
To produce an oncolytic virus in which thymidine kinase (TK) gene is deleted and which expresses a mutated herpes simplex virus thymidine kinase (HSV1-TK) gene, a TK region in the Western Reserve strain wild-type vaccinia virus was subjected to substitution using (as a shuttle vector) pUC57amp+ plasmid (Genewiz, USA) into which synthesized mutated type 1 HSV-TK gene (pSE/L promoter) of SEQ ID NO: 1 and firefly luciferase reporter (p7.5 promoter) gene were recombined. An oncolytic virus was obtained in the same manner as in Preparation Example 1.2 using the shuttle vector as constructed above, and this oncolytic virus was designated WOTS-418.
To identify an additional effect caused by administration of hydroxyurea upon co-administration of an oncolytic virus and a PD-1 inhibitor (CD279, BioXCell), which is one of the immune checkpoint inhibitors, an experiment was conducted using mouse renal cancer cell-transplanted mice.
First, Balb/c mice (female, 8-week-old) purchased from ORIENT BIO (Busan, Korea) were subjected to a one-week acclimatization period, and then allografted with Renca cancer cell line (Korea Cell Line Bank) at 5×106 cells. The tumor volume was observed until it reached 200 mm3 to 300 mm3, and then oncolytic virus (Wyeth VVtk−) administration was started. The oncolytic virus has limited proliferation in an allograft model.
The produced mouse renal cancer cell-transplanted mice were divided into 5 groups (n=5). The group receiving intraperitoneal administration of saline was set as a negative control group, the group receiving the mouse PD-1 inhibitor, the group receiving intratumoral administration of the oncolytic virus (Wyeth VVtk−, 1×107 pfu), and the group receiving co-administration of the oncolytic virus (Wyeth VVtk−, 1×107 pfu) and the PD-1 inhibitor were set as positive control groups. In addition, the group receiving co-administration of the oncolytic virus (Wyeth VVtk−, 1×107 pfu), the PD-1 inhibitor, and hydroxyurea (30 mg/kg) was set as an experimental group. Here, the oncolytic virus was intratumorally administered once; the PD-1 inhibitor was intraperitoneally administered once every 2 days on days 14, 16, 18, and 20; and the hydroxyurea was intraperitoneally administered 6 times per week.
Tumor volumes were measured on days 0, 4, 10, 14, 17, and 21 after the drug administration to the mice of each group. As a result, it was identified that the tumor volume in the mice of the experimental group was significantly suppressed as compared with the tumor volume in the mice of the positive control groups (
To identify an additional effect caused by administration of hydroxyurea upon co-administration of an oncolytic virus and a CTLA-4 inhibitor (B7-H1, BioXCell), which is an immune checkpoint inhibitor, an experiment was conducted using mouse renal cancer cell-transplanted mice.
First, Balb/c mice (female, 8-week-old) purchased from ORIENT BIO (Busan, Korea) were subjected to a one-week acclimatization period, and then allografted with Renca cancer cell line (Korea Cell Line Bank) at 5×106 cells. The tumor volume was observed until it reached 50 mm3 to 150 mm3, and then oncolytic virus (Wyeth VVtk−) administration was started. The oncolytic virus has limited proliferation in an allograft model.
The produced mouse renal cancer cell-transplanted mice were divided into 5 groups (n=6). The group receiving intraperitoneal administration of saline was set as a negative control group, the group receiving the CTLA-4 inhibitor, the group receiving intratumoral administration of the oncolytic virus (Wyeth 1×107 pfu), and the group receiving co-administration of the oncolytic virus (Wyeth VVtk−, 1×107 pfu) and the CTLA-4 inhibitor were set as positive control groups. In addition, the group receiving co-administration of the oncolytic virus (Wyeth VVtk−, 1×107pfu), the CTLA-4 inhibitor, and hydroxyurea (30 mg/kg) was set as an experimental group. Here, the oncolytic virus was intratumorally administered once; the CTLA-4 inhibitor was intraperitoneally administered once every 2 days on days 3, 5, 7, and 9; and the hydroxyurea was intraperitoneally administered 6 times per week.
Tumor volumes were measured on days 0, 4, 7, 10, 14, and 17 after the drug administration to the mice of each group. As a result, it was identified that the tumor volume in the mice of the experimental group was significantly suppressed as compared with the tumor volume in the mice of the positive control groups (
To identify an additional effect caused by administration of hydroxyurea upon co-administration of an oncolytic virus and a PD-L1 inhibitor (CD152, BioXCell), which is one of the immune checkpoint inhibitors, an experiment was conducted using mouse renal cancer cell-transplanted mice.
First, Balb/c mice (female, 8-week-old) purchased from ORIENT BIO (Busan, Korea) were subjected to a one-week acclimatization period, and then allografted with Renca cancer cell line (Korea Cell Line Bank) at 5×106 cells. The tumor volume was observed until it reached 50 mm3 to 100 mm3, and then oncolytic virus (Wyeth VVtk−) administration was started. The oncolytic virus has limited proliferation in an allograft model.
The produced mouse renal cancer cell-transplanted mice were divided into 5 groups (n=6). The group receiving intraperitoneal administration of saline was set as a negative control group, the group receiving the PD-L1 inhibitor (300 μg/mouse), the group receiving intratumoral administration of the oncolytic virus (Wyeth VVtk−, 1×107 pfu), and the group receiving co-administration of the oncolytic virus (Wyeth 1×107 pfu) and the PD-L1 inhibitor were set as positive control groups. In addition, the group receiving co-administration of the oncolytic virus (Wyeth VVtk−, 1×107 pfu), the PD-L1 inhibitor, and hydroxyurea (30 mg/kg) was set as an experimental group. Here, the oncolytic virus was intratumorally administered once; the PD-L1 inhibitor was intraperitoneally administered on days 0, 3, 7, 10, 14, 17, and 21; and the hydroxyurea was intraperitoneally administered 6 times per week.
Tumor volumes were measured on days 0, 3, 7, 10, 14, 17, and 21 after the drug administration to the mice of each group. As a result, it was identified that the tumor volume in the mice of the experimental group was significantly suppressed as compared with the tumor volume in the mice of the positive control groups (
From these results, it was identified that an excellent mouse renal cancer inhibition effect was exhibited in a case where hydroxyurea is also administered upon co-administration of an oncolytic virus and an immune checkpoint inhibitor (PD-L1 inhibitor).
To identify an additional effect caused by administration of hydroxyurea upon co-administration of an oncolytic virus and a CTLA-4 inhibitor (B7-H1, BioXCell), an experiment was conducted using mouse breast cancer cell-transplanted mice.
First, Balb/c mice (female, 8-week-old) purchased from ORIENT BIO (Busan, Korea) were subjected to a one-week acclimatization period, and then allografted with 4T1 cancer cell line (Korea Cell Line Bank) at 1×106 cells. The tumor volume was observed until it reached 50 mm3 to 150 mm3, and then oncolytic virus (WR VVtk−) administration was started. The Western Reserve strain vaccinia virus-derived oncolytic virus (WR Wtk−) has stronger proliferative capacity in an allograft model than Wyeth strain vaccinia virus-derived oncolytic virus.
The produced mouse breast cancer cell-transplanted mice were divided into 5 groups (n=5). The group receiving intraperitoneal administration of saline was set as a negative control group, the group receiving the CTLA-4 inhibitor (300 μg/mouse), the group receiving intratumoral administration of the oncolytic virus (WR VVtk−, 133 107 pfu), and the group receiving co-administration of the oncolytic virus (WR VVtk−, 1×107 pfu) and the CTLA-4 inhibitor were set as positive control groups. In addition, the group receiving co-administration of the oncolytic virus (WR VVtk−, 1×107 pfu), the CTLA-4 inhibitor, and hydroxyurea (30 mg/kg) was set as an experimental group.
Here, the oncolytic virus was intratumorally administered twice; the CTLA-4 inhibitor was intraperitoneally administered on days 3, 5, 7, and 9; and the hydroxyurea was intraperitoneally administered 6 times per week.
Tumor volumes were measured on days 0, 3, 7, 10, and 14 after the drug administration to the mice of each group. As a result, it was identified that the tumor volume in the mice of the experimental group was significantly suppressed as compared with the tumor volume in the mice of the positive control groups (
In addition, it was identified that as for survival, the mice of the experimental group exhibited the best survival period and survival rate (
To identify an additional effect caused by administration of hydroxyurea upon co-administration of an oncolytic virus and a PD-L1 inhibitor (CD152, BioXCell), an experiment was conducted using mouse breast cancer cell-transplanted mice.
First, Balb/c mice (female, 8-week-old) purchased from ORIENT BIO (Busan, Korea) were subjected to a one-week acclimatization period, and then allografted with 4T1 cancer cell line (Korea Cell Line Bank) at 1×106 cells. The tumor volume was observed until it reached 50 mm3 to 100 mm3, and then Western Reserve strain vaccinia virus-derived oncolytic virus (WOTS-418) administration was started. The Western Reserve strain has stronger proliferative capacity in an allograft model than the Wyeth strain.
The produced mouse breast cancer cell-transplanted mice were divided into 5 groups (n=6). The group receiving intraperitoneal administration of saline was set as a negative control group, the group receiving the PD-L1 inhibitor (300 μg/mouse), the group receiving intratumoral administration of the oncolytic virus (WOTS-418, 1×107 pfu), and the group receiving co-administration of the oncolytic virus (WOTS-418, 1×107 pfu) and the PD-L1 inhibitor were set as positive control groups. In addition, the group receiving co-administration of the oncolytic virus (WOTS-418, 1×107 pfu), the PD-L1 inhibitor, and hydroxyurea (30 mg/kg) was set as an experimental group. Here, the oncolytic virus was intratumorally administered twice; the PD-L1 inhibitor was intraperitoneally administered on days 3, 5, 7, and 9; and the hydroxyurea was intraperitoneally administered 6 times per week.
Tumor volumes were measured on days 0, 3, 7, 10, and 14 after the drug administration to the mice of each group in Experimental Example 5.1. As a result, it was identified that the tumor volume in the mice of the experimental group was significantly suppressed as compared with the tumor volume in the mice of the positive control groups (
From these results, it was identified that a synergistic effect was exhibited in suppressing mouse breast cancer in a case where hydroxyurea is also administered upon co-administration of an oncolytic virus and an immune checkpoint inhibitor (PD-L1 inhibitor).
A 30-day survival rate was analyzed for the mice of each group in Experimental Example 5.1. As a result, it was identified that the mice of the experimental group had a higher survival rate than that in the mice of the negative and positive control groups.
To identify the safety upon co-administration of Western Reserve strain vaccinia virus (WR), a PD-L1 inhibitor, and hydroxyurea, a survival period was analyzed using mouse colorectal cancer cell-transplanted mice.
First, Balb/c mice purchased from ORIENT BIO (Busan, Korea) were subjected to a one-week acclimatization period, and then subcutaneously transplanted with a mouse colorectal cancer (CT-26) cell line (Korea Cell Line Bank) at 1×106 cells. After 7 days, the oncolytic virus (WR) and the PD-L1 inhibitor were intraperitoneally administered, and hydroxyurea was administered daily for 5 days from the next day. On the other hand, the Western Reserve strain vaccinia virus has stronger proliferative capacity in an allograft model than Wyeth strain vaccinia virus.
The produced mouse colorectal cancer cell-transplanted mice were divided into 5 groups (n=13). The group receiving intraperitoneal administration of saline was set as a negative control group, the group receiving the PD-L1 inhibitor (200 μg/mouse) alone, and the group receiving co-administration of the oncolytic virus (WOTS-418) and hydroxyurea (30 mg/kg) were set as positive control groups. In addition, the group receiving co-administration of the oncolytic virus (WR, 1×106 pfu; or WOTS-418, 1×107 pfu), the PD-L1 inhibitor, and hydroxyurea was set as an experimental group. Here, the oncolytic virus was intratumorally administered once; the PD-L1 inhibitor was intraperitoneally administered on days 1, 4, 8, and 11; and the hydroxyurea was intraperitoneally administered 5 times per week.
Survival curves for the mice of each group were analyzed. As a result, it was observed that the mice of the experimental group had the longest survival period as compared with the mice of the negative and positive control groups. From these results, it was identified that safety was improved in a case of co-administration of an oncolytic virus, an immune checkpoint inhibitor, and hydroxyurea.
To identify an additional effect caused by administration of hydroxyurea upon co-administration of Western Reserve Strain vaccinia virus and a CTLA-4 inhibitor (B7-H1, BioXCell), which is one of the immune checkpoint inhibitors, an experiment was conducted using mouse renal cancer cell-transplanted mice.
First, Balb/c mice (female, 8-week-old) purchased from ORIENT BIO (Busan, Korea) were subjected to a one-week acclimatization period, and then allografted with Renca cancer cell line (Korea Cell Line Bank) at 5×106 cells. The tumor volume was observed until it reached 30 mm3 to 50 mm3, and then Western Reserve strain vaccinia virus (WR) administration was started. The Western Reserve strain vaccinia virus has stronger proliferative capacity in an allograft model than Wyeth strain vaccinia virus.
The produced mouse renal cancer cell-transplanted mice were divided into 4 groups (n=4). The group receiving intraperitoneal administration of saline was set as a negative control group, the group receiving co-administration of the Western Reserve strain vaccinia virus (WR, 1×105 pfu) and hydroxyurea (30 mg/kg), and the group receiving co-administration of the Western Reserve strain vaccinia virus and the CTLA-4 inhibitor (150 μg/mouse) were set as positive control groups. In addition, the group receiving administration of the Western Reserve strain vaccinia virus, the CTLA-4 inhibitor, and hydroxyurea was set as an experimental group. Here, the Western Reserve strain vaccinia virus was intratumorally administered once; the CTLA-4 inhibitor was intraperitoneally administered on days 2, 4. 6, and 8; and the hydroxyurea was intraperitoneally administered 4 times per week.
Tumor volumes were measured on days 0, 3, and 7 after the drug administration to the mice of each group. As a result, it was identified that the tumor volume in the mice of the experimental group was significantly suppressed as compared with the tumor volume in the mice of the positive control groups (
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2019/010850 | 8/26/2019 | WO |
